WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Options
Query Language
Stem
Sort by:
List Length
Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2007077435) PHARMACEUTICAL COMPOUNDS
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2007/077435 International Application No.: PCT/GB2006/004954
Publication Date: 12.07.2007 International Filing Date: 29.12.2006
IPC:
A61K 31/4155 (2006.01) ,A61K 31/4184 (2006.01) ,C07D 403/04 (2006.01) ,A61P 35/00 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
41
having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
415
1,2-Diazoles
4155
not condensed and containing further heterocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
41
having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
4164
1,3-Diazoles
4184
condensed with carbocyclic rings, e.g. benzimidazoles
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
403
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/167
02
containing two hetero rings
04
directly linked by a ring-member-to-ring- member bond
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
Applicants: BERDINI, Valerio[IT/GB]; GB (UsOnly)
CURRY, Jayne, Elizabeth[GB/GB]; GB (UsOnly)
GALLAGHER, Neil, James[IE/CH]; CH (UsOnly)
GILL, Adrian, Liam[GB/GB]; GB (UsOnly)
LYONS, John, Francis[IE/GB]; GB (UsOnly)
ASTEX THERAPEUTICS LIMITED[GB/GB]; 436 Cambridge Science Park Milton Road Cambridge CB4 0QA, GB (AllExceptUS)
Inventors: BERDINI, Valerio; GB
CURRY, Jayne, Elizabeth; GB
GALLAGHER, Neil, James; CH
GILL, Adrian, Liam; GB
LYONS, John, Francis; GB
Agent: HUTCHINS, Michael, Richard; Elkington and Fife LLP Prospect House 8 Pembroke Road Sevenoaks Kent TN13 1XR, GB
Priority Data:
0526607.730.12.2005GB
60/755,33930.12.2005US
60/806,21829.06.2006US
Title (EN) PHARMACEUTICAL COMPOUNDS
(FR) COMPOSES PHARMACEUTIQUES
Abstract:
(EN) The use of a compound for the manufacture of a medicament for the prophylaxis or treatment of: A. a disease state or condition mediated by a kinase which is BCR-abl, VEGFR, PDGFR, EGFR, Flt3, JAK (e.g. JAK2 or JAK3), C-abl, PDKl , Chk (e.g. Cbkl or Chk2), FGFR (e.g. FGFR3), Ret, Eph (e.g. EphB2 or EphB4), or Src (e.g. cSrc); or B. a cancer in which the cancer cells thereof contain a drug resistant kinase mutation which is: (a) a threonine gatekeeper mutation; or (b) a drug-resistant gatekeeper mutation; or (c)an imatinib resistant mutation; or (d) a nilotinib resistant mutation; or (e) a dasatinib resistant mutation; or (f) a T670I mutation in KIT; or (g) a T674I mutation in PDGFR; or (h) T790M mutation in EGFR; or (i) a T315I mutation in abl; or C. a cancer which expresses a mutated molecular target which is a mutated form of BCRabl, c-kit, PDGF, EGF receptor or ErbB2; or D. a disease mediated by a kinase containing a mutation in a region of the protein that binds to or interacts with other cancer agents but does not bind to or interact with the compounds of formula (I) or (I’), for example a mutated kinase selected from c-abl, c-kit, PDGFR including PDGFR-beta and PDGFR-alpha, and ErbB family members such as EGFR (ErbBl), HER2 (ErbB2), ErbB3, and ErbB4, members of the Ephrin receptor family including EphA1, EphA2, EphA3, EphA4, EphA5, EphA8, EphA10, EphB1, EphB2, EphB3, EphB5, EphB6, c-Src and kinases of the JAK family such as TYK2; wherein the compound is a compound of the formula (I or I’) : or a salt, solvate, tautomer or N-oxide thereof; wherein R0’, R1, R1’, R2’, R3’, R4’, A’, X’, E, A and M are as defined in the claims.
(FR) La présente invention concerne l’utilisation d’un composé pour la fabrication d’un médicament destiné à la prophylaxie ou au traitement de : A. un état pathologique ou une affection lié à une kinase qui est BCR-abl, VEGFR, PDGFR, EGFR, Flt3, JAK (p. ex. JAK2 ou JAK3), C-abl, PDKl, Chk (p. ex. Cbkl ou Chk2), FGFR (p. ex. FGFR3), Ret, Eph (p. ex. EphB2 ou EphB4) ou Src (p. ex. cSrc); ou B. un cancer dans lequel les cellules cancéreuses contiennent une mutation pharmacorésistante de la kinase, qui est : (a) une mutation de contrôle d’accès de la thréonine ; ou (b) une mutation de contrôle d’accès pharmacorésistante ; ou (c)une mutation résistante à l’imatinib; ou (d) une mutation résistante au nilotinib ; ou (e) une mutation résistante au dasatinib; ou (f) une mutation T670I dans KIT; ou (g) une mutation T674I dans PDGFR; ou (h) une mutation T790M dans EGFR; ou (i) une mutation T315I dans abl; ou C. un cancer exprimant une cible moléculaire mutée qui est une forme mutée de BCRabl, c-kit, PDGF, le récepteur EGF ou ErbB2; ou D. une maladie liée à une kinase contenant une mutation dans une région de la protéine qui se lie à ou interagit avec d’autres agents cancéreux mais ne se lie pas ou n’interagit pas avec les composés de formule (I) ou (I’), par exemple une kinase mutée sélectionnée parmi c-abl, c-kit, PDGFR y compris PDGFR-bêta et PDGFR-alpha, et les membres de la famille ErbB tels qu’EGFR (ErbBl), HER2 (ErbB2), ErbB3 et ErbB4, les membres de la famille des récepteurs de l’éphrine incluant EphA1, EphA2, EphA3, EphA4, EphA5, EphA8, EphA10, EphB1, EphB2, EphB3, EphB5, EphB6, c-Src et des kinases de la famille JAK telles que TYK2; le composé étant un composé de formule (I ou I’) : ou un sel, solvate, tautomère ou N-oxyde dudit composé; R0’, R1, R1’, R2’, R3’, R4’, A’, X’, E, A et M étant tels que définis dans les revendications.
front page image
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)